Mitochondrial Dysfunction Induced by a Novel Salicylate‐Based 1,2,3‐Triazole Salt With Potent Antileishmanial Activity
Chemical Biology & Drug Design · 2025
DOI: 10.1111/cbdd.70227 ↗At a glance
Journal article in Chemical Biology & Drug Design, 2025. Written by Bruno A De Oliveira and 8 co-authors. Institution: Department of Chemistry, Institute of Exact Sciences, Federal University of Juiz de Fora, Juiz de Fora, Minas Gerais, Brazil. Major MEDLINE topics: Triazoles, Antiprotozoal Agents, Mitochondria, Salicylates. 50 references. The full text is freely available (open access, CC BY 4.0). Funded by: Fundação de Amparo à Pesquisa do Estado de Minas Gerais, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, Conselho Nacional de Desenvolvimento Científico e Tecnológico.
Abstract (original language)
Leishmaniasis is a neglected disease caused by Leishmania spp., with limited treatment options and no available vaccine. In this study, novel 1,2,3‐triazole derivatives 4‐substituted with salicylic esters and their salts were synthesized and evaluated against L. amazonensis . While neutral compounds were inactive, their salts effectively inhibited both promastigote and intracellular amastigote growth. Compound 7 exhibited the highest antileishmanial activity and selectivity (IC 50 against amastigotes of 6.23 ± 0.35 μM; SI of 17.81), surpassing miltefosine, the positive control. Additionally, this compound exhibited no hemolytic effect. Studies further demonstrated that at early time points (6 h), treatment with compound 7 led to a marked increase in total ROS and mitochondrial superoxide levels, although no change in mitochondrial membrane potential was detected, indicating an initial oxidative imbalance without immediate effects on ΔΨm. However, after 24 h of treatment, this sustained oxidative stress resulted in pronounced mitochondrial membrane potential hyperpolarization, while elevated ROS levels persisted. Throughout these assays, plasma membrane integrity remained unaffected in treated L. amazonensis promastigotes. In silico analyses suggested favorable pharmacokinetic properties and oral bioavailability. Collectively, these findings highlight compound 7 as a promising candidate for further studies, including in vivo assays using murine models of leishmaniasis.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Chemistry, Institute of Exact Sciences, Federal University of Juiz de Fora, Juiz de Fora, Minas Gerais, Brazil.
- Department of Parasitology, Microbiology and Immunology, Institute of Biological Sciences, Federal University of Juiz de Fora, Juiz de Fora, Minas Gerais, Brazil.
- Department of Veterinary Medicine, Faculty of Medicine, Federal University of Juiz de Fora, Juiz de Fora, Minas Gerais, Brazil.
ORCID profiles: Bruno A De Oliveira, Elaine Soares Coimbra
Funding
- Fundação de Amparo à Pesquisa do Estado de Minas Gerais
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
Cite
APA
De Oliveira, B. A., de Oliveira Lemos, A. S., Bastos, J. P. R. C., Antinarelli, L. M. R., de Freitas, A. L. R., Ribeiro, R. G. M., da Silva Neto, A. F., Coimbra, E. S., & Da Silva, A. D. (2025). Mitochondrial Dysfunction Induced by a Novel Salicylate‐Based 1,2,3‐Triazole Salt With Potent Antileishmanial Activity. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.70227
Vancouver
De Oliveira BA, de Oliveira Lemos AS, Bastos JPRC, Antinarelli LMR, de Freitas ALR, Ribeiro RGM, et al. Mitochondrial Dysfunction Induced by a Novel Salicylate‐Based 1,2,3‐Triazole Salt With Potent Antileishmanial Activity. Chemical Biology & Drug Design. 2025. doi:10.1111/cbdd.70227
BibTeX
@article{DeOliveira2025,
author = {De Oliveira, Bruno A and de Oliveira Lemos, Ari Sérgio and Bastos, João Pedro Reis Costa and Antinarelli, Luciana Maria Ribeiro and de Freitas, Ana Luiza Ribeiro and Ribeiro, Raissa Guedes Mattosinhos and da Silva Neto, Adolfo Firmino and Coimbra, Elaine Soares and Da Silva, Adilson David},
title = {Mitochondrial Dysfunction Induced by a Novel Salicylate‐Based 1,2,3‐Triazole Salt With Potent Antileishmanial Activity},
journal = {Chemical Biology & Drug Design},
year = {2025},
doi = {10.1111/cbdd.70227}
}
EUVIMED